Profile: Agenus Inc (AGEN.PH)
27 Sep 2016
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Company has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
The Company's Prophage vaccines are being studied in two different settings of glioblastoma multiforme (GBM): patients who have been newly diagnosed, as well as those with recurrent disease. QS-21 Stimulon is an adjuvant, a substance added to a vaccine or other immunotherapy that is intended to enhance immune response to the target antigens.
The Company competes with Bristol-Myers Squibb, Merck, Ono Pharmaceuticals, AstraZeneca, Curetech, Pfizer, Tesaro, Novartis, Roche, Neon Therapeutics, Gritstone Oncology, Aduro Biotech, Advaxis Inc., Inovio Pharmaceutical Inc., Oncolytics Biotech Inc., Oncothyreon, Eisai, Arbor Pharmaceuticals, Innocell Corp, ImmunoCellular Therapeutics, Northwest Biotherapeutics, Immatics, Activartis Biotech, Idera, Colby, Dynavax, Intercell, GlaxoSmithKline plc, Adjuvance Technologies, Inc., CSL Limited and Novavax, Inc.
3 Forbes Rd
LEXINGTON MA 02421-7305
Company Web Links
- BRIEF-Agenus Q2 loss per share $0.33
- BRIEF-Agenus' chief financial officer, C.Evan Ballantyne to resign
- BRIEF-Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
- BRIEF-Agenus announces lead product candidate selection in Merck collaboration
- BRIEF-Agenus reports Q1 loss per share $0.37